Abbott Laboratories (ABT) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $1.31
- EPS estimate
- $1.31
- EPS surprise
- +0.00%
- Revenue surprise
- +0.58%
- Revenue
- $12.6B
- Revenue estimate
- $12.5B
- Reported
- Jul 16, 2026
Abbott reported Q2 2026 results on July 16, 2026. Earnings per share were $1.31, exactly matching the $1.31 estimate. Revenue was $12.6 billion against a $12.5 billion consensus, a 0.58% beat, and the highest quarterly figure in the table. Compared with Q2 2025, EPS rose about 4% from $1.26, while revenue rose about 14% from $11.1 billion.
Annual EPS fell from $5.34 in 2022 to $4.44 in 2023, then recovered to $4.67 in 2024 and $5.15 in 2025. The quarterly high in the table was $1.73 in Q1 2022 and the low was $0.98 in Q1 2024. The first half of 2026 adds up to $2.46 per share, about 5% more than a year earlier, while revenue grew faster, by about 11%. Over the last 20 quarters, Abbott beat the EPS estimate 17 times, missed twice and matched once. Surprises have narrowed. 2022 brought double-digit beats, while every result since the start of 2024 landed within 3.17% of the estimate.
Abbott reported Q3 between October 15 and October 20 in each of the past five years. That points to mid-October 2026 for the next report. It will show whether revenue growth keeps outpacing EPS growth.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 16, 2026 | $1.31 | $1.31 | +0.00% | $12.6B | SEC |
| Q1 2026 | Apr 16, 2026 | $1.14 | $1.15 | +0.46% | $11.2B | SEC |
| Q4 2025 | Jan 22, 2026 | $1.50 | $1.50 | +0.27% | $11.5B | SEC |
| Q3 2025 | Oct 15, 2025 | $1.30 | $1.30 | −0.21% | $11.4B | SEC |
| Q2 2025 | Jul 17, 2025 | $1.26 | $1.26 | +0.33% | $11.1B | SEC |
| Q1 2025 | Apr 16, 2025 | $1.07 | $1.09 | +1.66% | $10.4B | SEC |
| Q4 2024 | Jan 22, 2025 | $1.34 | $1.34 | −0.19% | $11.0B | SEC |
| Q3 2024 | Oct 16, 2024 | $1.20 | $1.21 | +0.65% | $10.6B | SEC |
| Q2 2024 | Jul 18, 2024 | $1.11 | $1.14 | +3.17% | $10.4B | SEC |
| Q1 2024 | Apr 17, 2024 | $0.96 | $0.98 | +2.62% | $10.0B | SEC |
| Q4 2023 | Jan 24, 2024 | $1.19 | $1.19 | +0.03% | $10.2B | SEC |
| Q3 2023 | Oct 18, 2023 | $1.10 | $1.14 | +3.57% | $10.1B | SEC |
| Q2 2023 | Jul 20, 2023 | $1.05 | $1.08 | +2.89% | $10.0B | SEC |
| Q1 2023 | Apr 19, 2023 | $0.99 | $1.03 | +4.01% | $9.7B | SEC |
| Q4 2022 | Jan 25, 2023 | $0.93 | $1.03 | +11.27% | $10.1B | SEC |
| Q3 2022 | Oct 19, 2022 | $0.94 | $1.15 | +21.93% | $10.4B | SEC |
| Q2 2022 | Jul 20, 2022 | $1.13 | $1.43 | +26.86% | $11.3B | — |
| Q1 2022 | Apr 20, 2022 | $1.47 | $1.73 | +18.09% | $11.9B | — |
| Q4 2021 | Jan 26, 2022 | $1.21 | $1.32 | +9.41% | $11.5B | — |
| Q3 2021 | Oct 20, 2021 | $0.94 | $1.40 | +48.16% | $10.9B | — |
Quarterly revenue
Frequently asked questions
When did Abbott Laboratories (ABT) last report earnings?
Abbott Laboratories last reported on Jul 16, 2026, covering fiscal Q2 2026.
Did ABT beat earnings estimates?
Abbott Laboratories reported EPS of $1.31 for Q2 2026, in line with the $1.31 consensus estimate.
How much revenue did ABT report last quarter?
Abbott Laboratories reported $12.6B in revenue for Q2 2026, against a consensus estimate of $12.5B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.